Using Reverse Genetics to Improve Influenza Vaccines

Reverse Genetics of RNA Viruses: Applications and Perspectives

Volumn , Issue , 2012, Pages 224-249

  Elderfield, Ruth A ^a   Hartgroves, Lorian C S ^a   Barclay, Wendy S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Genetic manipulation of standard PR8 by reverse genetics; HPAI threat, ability to transmit between humans; Influenza vaccines in influenza control; Influenza, with a single stranded, negative sense, RNA virus; Mutations responsible for ts and ca phenotypes of influenza virus vaccines; Novel influenza virus, adapting to infection transmission in humans; Reverse genetics for recombinant influenza A, B, C viruses; Reverse genetics for vaccine seed in novel influenza A; Reverse genetics in improving influenza vaccines; Strategies, in improving safety yield of influenza vaccines

Indexed keywords

EID: 84888685960     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118405338.ch8     Document Type: Chapter

References (102)

1. Akarsu, H., Iwatsuki-Horimoto, K., Noda, T., Kawakami, E., Katsura, H., Baudin, F., Horimoto, T. and Kawaoka, Y. 2011. Structure-based design of NS2 mutants for attenuated influenza A virus vaccines. Virus Research 155: 240-248.
2. Chan, W., Zhou, H., Kemble, G. and Jin, H. 2008. The cold adapted and temperature sensitive influenza A/Ann Arbor/6/60 virus, the master donor virus for live attenuated influenza vaccines, has multiple defects in replication at the restrictive temperature. Virology 380: 304-311.
3. Chen, Z., Aspelund, A., Kemble, G. and Jin, H. 2006. Genetic mapping of the coldadapted phenotype of B/Ann Arbor/1/66, the master donor virus for live attenuated influenza vaccines (Flumist). Virology 345: 416-423.
4. Cox, N. J. and Subbarao, K. 2000. Global epidemiology of influenza: past and present. Annual Review of Medicine 51: 407-421.
5. Crescenzo-Chaigne, B., and Van Der Werf, S. 2007. Rescue of influenza C virus from recombinant DNA. Journal of Virology 81(20): 11282-11289.
6. Dauber, B., Heins, G., and Wolff, T. 2004. The influenza B virus nonstructural NS1 protein is essential for efficient viral growth and antagonizes beta interferon induction. Journal of Virology 78(4): 1865-1872.
7. De Wit, E., Spronken, M.I., Vervaet, G., Rimmelzwaan, G.F., Osterhaus, A.D. and Fouchier, R.A. 2007. A reverse-genetics system for influenza A virus using T7 RNA polymerase. Journal of General Virology 88(Pt 4): 1281-1287.
8. Desmyter, J., Melnick, J. L., and Rawls, W. E. 1968. Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). Journal of Virology 2(10): 955-961.
9. Egorov, A., Brandt, S., Sereinig, S., Romanova, J., Ferko, B., Katinger, D., Grassauer, A., et al. 1998. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. Journal of Virology 72: 6437- 6441.
10. Enami, M., Luytjes, W., Krystal, M. and Palese, P. 1990. Introduction of sitespecific mutations into the genome of influenza virus. PNAS 87: 3802-3805.
11. Enami, M. and Palese, P. 1991. High-efficiency formation of influenza virus transfectants. Journal of Virology 65: 2711-2713.
12. Ferko, B., Kittel, C., Romanova, J., Sereinig, S., Katinger, H. and Egorov, A. 2006. Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. Journal of Virology 80(23): 11621-11627.
13. Flandorfer, A., García-Sastre, A., Basler, C. F., and Palese, P. 2003. Chimeric influenza A viruses with a functional influenza B virus neuraminidase or hemagglutinin. Journal of Virology 77(17): 9116-9123.
14. Fodor, E., Devenish, L., Engelhardt, O. G., Palese, P., Brownlee, G. G. and GarciaSastre, A. 1999. Rescue of influenza A virus from recombinant DNA. Journal of Virology 73: 9679-9682.
15. Francis, T., JR. 1953. Vaccination against influenza. Bulletin of the World Health Organization 8: 725-741.
16. Fujii, K., Fujii, Y., Noda, T., Muramoto, Y., Watanabe, T., Takada, A., Goto, H., et al. 2005. Importance of both the coding and the segment-specific noncoding regions of the influenza A virus NS segment for its efficient incorporation into virions. Journal of Virology 79: 3766-3774.
17. Gao, Q. and Palese, P. 2009. Rewiring the RNAs of influenza virus to prevent reassortment. PNAS 106: 15891-15896.
18. Garcia-Sastre, A., Egorov, A., Matassov, D., Brandt, S., Levy, D. E., Durbin, J. E., Palese, P. andMuster, T. 1998. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252: 324-330.
19. Garten, R. J., Davis, C. T., Russell, C. A., Shu, B., Lindstrom, S., Balish, A., Sessions, W. M., Xu, X., et al. 2009. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325: 197-201.
20. Ghendon, Y. Z., Klimov, A. I., Alexandrova, G. I. and Polezhaev, F. I. 1981. Analysis of genome composition and reactogenicity of recombinants of cold-adapted and virulent virus strains. Journal of General Virology 53: 215-224.
21. Girard, M. P., Katz, J., Pervikov, Y., Palkonyay, L. and Kieny, M. P. 2010. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010. Vaccine 28: 6811-6820.
22. Hai, R., García-Sastre, A., Swayne, D. E., and Palese, P. 2011. A reassortmentincompetent live attenuated influenza virus vaccine for protection against pandemic virus strains. Journal of Virology 85(14): 6832-6843.
23. Hai, R., Martínez-Sobrido, L., Fraser, K. A., Ayllon, J., García-Sastre, A., and Palese, P. 2008. Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. Journal of Virology 82(21): 10580-10590.
24. Hale, B. G., Randall, R. E., Ortin, J. and Jackson, D. 2008. The multifunctional NS1 protein of influenza A viruses. Journal of General Virology 89: 2359-2376.
25. Hartgroves, L. C., Koudstaal, W., McLeod, C., Moncorge, O., Thompson, C. I., Ellis, J., Bull, C., et al. 2010. Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs. Vaccine 28: 2973-2979.
26. Harvey, R., Nicolson, C., Johnson, R. E., Guilfoyle, K. A.,Major, D. L., Robertson, J. S. and Engelhardt, O. G. 2010. Improved haemagglutinin antigen content in H5N1 candidate vaccine viruses with chimeric haemagglutinin molecules. Vaccine 28: 8008-8014.
27. Hatta, M., and Kawaoka, Y. 2003. The NB protein of influenza B virus is not necessary for virus replication in vitro. Journal of Virology 77(10): 6050-6054.
28. Herrler, G., Dürkop, I., Becht, H and Klenk, HD. 1988. The glycoprotein of influenza C virus is the haemagglutinin, esterase and fusion factor. The Journal of General Virology 69(Pt 4): 839-846.
29. Hilton, L., Moganeradj, K., Zhang, G., Chen, Y.-H., Randall, R. E., McCauley, J. W., and Goodbourn, S. 2006. The NPro product of bovine viral diarrhea virus inhibits DNA binding by interferon regulatory factor 3 and targets it for proteasomal degradation. Journal of Virology 80(23): 11723-11732.
30. Hoffmann, E., Krauss, S., Perez, D., Webby, R. and Webster, R. G. 2002. Eightplasmid system for rapid generation of influenza virus vaccines. Vaccine 20: 3165.
31. Hoffmann, E., Mahmood, K., Chen, Z., Yang, C. F., Spaete, J., Greenberg, H. B., Herlocher, M. L., et al. 2005. Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66. Journal of Virology 79: 11014-11021.
32. Hoffmann, E., Mahmood, K., Yang, C.-F., Webster, R. G., Greenberg, H. B., and Kemble, G. 2002. Rescue of influenza B virus from eight plasmids. PNAS 99(17): 11411-11416.
33. Hongo, S., Sugawara, K., Muraki, Y., Matsuzaki, Y., Takashita, E., Kitame, F., and Nakamura, K. 1999. Influenza C virus CM2 protein is produced from a 374-amino-acid protein (P42) by signal peptidase cleavage. Journal of Virology 73(1): 46-50.
34. Horimoto, T., Takada, A., Fujii, K., Goto, H., Hatta, M., Watanabe, S., IwatsukiHorimoto, K., et al. 2006. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 24: 3669-3676.
35. Imai, M., Watanabe, S., Ninomiya, A., Obuchi, M., and Odagiri, T. 2004. Influenza B virus BM2 protein is a crucial component for incorporation of viral ribonucleoprotein complex into virions during virus assembly. Journal of Virology 78(20): 11007-11015.
36. Jackson, D., Cadman, A., Zurcher, T., and Barclay, W. S. 2002. A reverse genetics approach for recovery of recombinant influenza B viruses entirely from cDNA. Journal of Virology 76(22): 11744-11747.
37. Jackson, R. J., Ramsay, A. J., Christensen, C. D., Beaton, S., Hall, D. F., and Ramshaw, I.A. 2001. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. Journal of Virology. 75(3): 1205-1210.
38. Jin, H., Lu, B., Zhou, H., Ma, C., Zhao, J., Yang, C. F., Kemble, G. and Greenberg, H. 2003. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 306(1): 18-24.
39. Karron, R.A., Talaat, K., Luke, C., Callahan, K., Thumar, B., Dilorenzo, S., McAuliffe, J., et al. 2009. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine, 27(36): 4953-4960.
40. Keawcharoen, J., Spronken, M. I., Vuong, O., Bestebroer, T. M., Munster, V. J., Osterhaus, A. D., Rimmelzwaan, G. F. and Fouchier, R. A. 2010. Repository of Eurasian influenza A virus hemagglutinin and neuraminidase reverse genetics vectors and recombinant viruses. Vaccine 28: 5803-5809.
41. Kilbourne, E. D. 1969. Future influenza vaccines and the use of genetic recombinants. Bulletin of the World Health Organization 41: 643-645.
42. Kittel, C., Ferko, B., Kurz,M., Voglauer, R., Sereinig, S., Romanova, J., Stiegler, G. et al. 2005. Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment. Journal of Virology 79(16): 10672-10677.
43. Koudstaal, W., Hartgroves, L., Havenga, M., Legastelois, I., Ophorst, C., Sieuwerts, M., Zuijdgeest, D., et al. W. 2009. Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics. Vaccine 27: 2588-93.
44. Kreijtz, J. H., Fouchier, R. A. and Rimmelzwaan, G. F. 2011. Immune responses to influenza virus infection. Virus Research 162(1-2): 19-30.
45. Li, S., Liu, C., Klimov, A., Subbarao, K., Perdue, M. L., Mo, D., Ji, Y., et al. 1999. Recombinant Influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. Journal of Infectious Diseases 179: 1132-1138.
46. Luytjes, W., Krystal, M., Enami, M., Parvin, J. D. and Palese, P. 1989. Amplification, expression, and packaging of foreign gene by influenza virus. Cell 59: 1107-1113.
47. Maassab, H. F. 1967. Adaptation and growth characteristics of influenza virus at 25? C. Nature 213: 612.
48. Massin, P., Rodrigues, P., Marasescu, M., Van Der Werf, S. and Naffakh, N. 2005. Cloning of the chicken RNA polymerase I promoter and use for reverse genetics of Influenza A viruses in avian cells. Journal of Virology 79(21): 13811- 13816.
49. McAuley, J. L., Hornung, F., Boyd, K. L., Smith, A. M., McKeon, R., Bennink, J., Yewdell, J. W. and McCullers, J. A. 2007. Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe 2: 240-249.
50. Minor, P. D., Engelhardt, O. G.,Wood, J. M., Robertson, J. S., Blayer, S., Colegate, T., Fabry, L., et al. 2009. Current challenges in implementing cell-derived influenza vaccines: Implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 27: 2907-2913.
51. Murakami, S., Horimoto, T., Mai Le, Q., Nidom, C. A., Chen, H., Muramoto, Y., Yamada, S., et al. 2008a. Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells. Journal of Virology 82: 10502-10509.
52. Murakami, S., Horimoto, T., Yamada, S., Kakugawa, S., Goto, H. and Kawaoka, Y. 2008b. Establishment of canine RNA polymerase I-driven reverse genetics for influenza A virus: its application for H5N1 vaccine production. Journal of Virology 82: 1605-1609.
53. Muraki, Y. and Hongo, S., 2010. The molecular virology and reverse genetics of influenza C virus. Japanese Journal of Infectious Diseases 63(3): 157-165.
54. Muraki, Y., Murata, T., Takashita, E., Matsuzaki, Y., Sugawara, K. and Hongo, S. 2007. A mutation on influenza C virus M1 protein affects virion morphology by altering the membrane affinity of the protein. Journal of Virology 81(16): 8766-7873.
55. Nakagawa, N., Natsumi, H., and Toshimasa, N. 2009. Cocirculation of antigenic variants and the vaccine-type virus during the 2004-2005 influenza B virus epidemics in Japan. Journal of Clinical Microbiology 47(2): 352-357.
56. Nerome, R. Hiromoto, Y., Sugita, S., Tanabe, N., Ishida, M., Matsumoto, M., Lindstrom, S.E., et al. 1998. Evolutionary characteristics of influenza B virus since its first isolation in 1940: dynamic circulation of deletion and insertion mechanism. Archives of Virology 143, 8, 1569-1583.
57. Neumann, G., Fujii, K., Kino, Y. and Kawaoka, Y. 2005. An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. PNAS 102: 16825-16829.
58. Neumann, G., Watanabe, T., Ito, H., et al. 1999. Generation of influenza A viruses entirely from cloned cDNAs. PNAS 96: 9345-9350.
59. Nicholson, K. G., Tyrrell, D. A., Oxford, J. S., et al. 1987. Infectivity and reactogenicity of reassortant cold-adapted influenza A/Korea/1/82 vaccines obtained from the USA and USSR. Bulletin of the World Health Organization 65: 295-301.
60. Nicholson, K. G., Wood, J. M. and Zambon, M. 2003. Influenza. The Lancet 362: 1733.
61. Nitsch-Osuch, A., Kuchar, E., Gyrczuk, E., et al. 2010. Clinical manifestations of influenza caused by A/H1N1v virus among children and teenagers consulted in general practice. European Journal of Medical Research 15 Suppl. 2: 105-107.
62. Noda, T., Sagara, H., Yen, A., Takada, A., et al. 2006. Architecture of ribonucleoprotein complexes in influenza A virus particles. Nature 439: 490-492.
63. Ohwada, K., Kitame, F., Sugawara, K., et al. 1987. Distribution of the antibody to influenza C virus in dogs and pigs in Yamagata Prefecture, Japan. Microbiology and Immunology, 31(12): 1173-1180.
64. Osterhaus, A. D., Rimmelzwaan, G. F., Martina, B. E., Bestebroer, T. M., and Fouchier, R. A. 2000. Influenza B virus in seals. Science (New York, N.Y.) 288(5468): 1051-1053.
65. Ozaki, H., Govorkova, E.A., Li, C., Xiong, X.,Webster, R.G. andWebby, R.J. 2004. Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics. Journal of Virology 78(4): 1851-1857.
66. Ozawa, M., Victor, S.T., Taft, A.S., Yamada, S., Li, C., Hatta, M., Das, S.C., et al. 2011. Replication-incompetent influenza A viruses that stably express a foreign gene. Journal of General Virology 92(Pt 12): 2879-2888.
67. Pachler, K., Mayr, J., and Vlasak, R. 2010. A seven plasmid-based system for the rescue of influenza C virus. Journal of Molecular and Genetic Medicine 4: 239-246.
68. Parvin, J. D., Palese, P., Honda, A., Ishihama, A. and Krystal, M. 1989. Promoter analysis of influenza virus RNA polymerase. Journal of Virology 63: 5142- 5152.
69. Pekosz, A., and Lamb, R. A. 1998. Influenza C virus CM2 integral membrane glycoprotein is produced from a polypeptide precursor by cleavage of an internal signal sequence. PNAS 95(22): 13233-13238.
70. Perez, J.T., Pham, A.M., Lorini, M.H., Chua, M.A., Steel, J. and Tenoever, B.R. 2009.MicroRNA-mediated specifis-specific attenuation of influenza A virus. Nature Biotechnology 27(6): 572-576.
71. Phipps-Yonas, H., Seto, J., Sealfon, S. C., Moran, T. M. and Fernandez-Sesma, A. 2008. Interferon-beta pretreatment of conventional and plasmacytoid human dendritic cells enhances their activation by influenza virus. PLoS Pathogens 4: e1000193.
72. Quinlivan, M., Zamarin, D., Garcia-Sastre, A., Cullinane, A., Chambers, T. and Palese, P. 2005. Attenuation of equine influenza viruses through truncations of the NS1 protein. Journal of Virology 79: 8431-8439.
73. Richt, J. A. and Garcia-Sastre, A. 2009. Attenuated influenza virus vaccines with modified NS1 proteins. Current Topics in Microbiology and Immunology 333: 177-195.
74. Richt, J.A., Lekcharoensuk, P., Lager, K.M., Vincent, A.L., Loiacono, C.M., Janke, B.H., Wu, W.H., et al. 2006 Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine. Journal of Virology 80(22): 11009-11018.
75. Robertson, J. S., Nicolson, C., Harvey, R., Johnson, R., Major, D., Guilfoyle, K., Roseby, S., Newman, R., et al. 2011. The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine 29: 1836-1843.
76. Romanova, J., Krenn, B. M., Wolschek, M., Ferko, B., Romanovskaja-Romanko, E., Morokutti, A., Shurygina, A. P., Nakowitsch, S., et al. 2009. Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS ONE 4: e5984.
77. Shaw, M.W., Choppin, P.W., and Lamb R.A. 1983. A previously unrecognized influenza B virus glycoprotein from a bicistronic mRNA that also encodes the viral neuraminidase. PNAS 80(16): 4879-4883.
78. Shinya, K., Ebina, M., Yamada, S., Ono, M., Kasai, N., and Kawaoka, Y. 2006. Avian flu: influenza virus receptors in the human airway. Nature 440(7083): 435-436.
79. Smith, D. J., Lapedes, A. S., De Jong, J. C., Bestebroer, T. M., Rimmelzwaan, G. F., Osterhaus, A. D. M. E. and Fouchier, R. A. M. 2004. Mapping the antigenic and genetic evolution of influenza virus. Science 305: 371-376.
80. Solorzano, A., Webby, R. J., Lager, K. M., Janke, B. H., Garcia-Sastre, A. and Richt, J. A. 2005. Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. Journal of Virology 79: 7535-7543.
81. Solorzano, A., Ye, J. and Perez, D. R. 2010. Alternative live-attenuated influenza vaccines based on modifications in the polymerase genes protect against epidemic and pandemic flu. Journal of Virology 84: 4587-4596.
82. Stech, J., Garn, H., Wegmann, M., Wagner, R. and Klenk, H. D. 2005. A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin. Nature Medicine 11: 683-689.
83. Stech, J., Garn, H., Herwig, A., Stech, O., Dauber, B.,Wolff, T., Mettenleiter, T. C., and Klenk, H. D. 2011. Influenza B virus with modified hemagglutinin cleavage site as a novel attenuated live vaccine. Journal of Infectious Diseases 204(10): 1483-1490.
84. Steel, J., Lowen, A. C., Pena, L., Angel, M., Solórzano, A., Albrecht, R., Perez, D. R., et al. 2009. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. Journal of Virology 83(4): 1742-53.
85. Stieneke-Grober, A., Vey, M., Angliker, H., Shaw, E., Thomas, G., Roberts, C., Klenk, H. D. and Garten,W. 1992. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO Journal 11: 2407-2414.
86. Subbarao, K., Chen, H., Swayne, D., Mingay, L., Fodor, E., Brownlee, G., Xu, X., et al. 2003. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305: 192-200.
87. Subbarao, K. and Katz, J. M. 2004. Influenza vaccines generated by reverse genetics. Current Topics in Microbiology and Immunology 283: 313-342.
88. Sun, S., Zhao, G., Xiao,W., Hu, J., Guo, Y., Yu, H.,Wu, X., et al. 2011. Age-related sensitivity and pathological differences in infections by 2009 pandemic influenza A (H1N1) virus. Virology Journal 8: 52.
89. Tong, S., Li, Y., Rivailler, P., Conrardy, C., Castillo, D. A. A., Chen, L. M., Recuenco, S., Ellison, J. A., Davis. C. T., York, I. A., Turmelle, A. S., Moran, D., Rogers, S., Shi, M., Tao, Y., Weil, M. R., Tang, K., Rowe, L. A. Sammons, S., Xu, X., Frace,M., Lindblade, K. A., Cox, N. J., Anderson, L. J., Rupprecht, C. E. and Donis, R. O. 2012. A distinct lineage of influenza A virus from bats. PNAS 2009, 4269-4274.
90. VanWielink, R., Harmsen, M. M., Martens, D. E., Peeters, B. P. H.,Wijffels, R. H., and Moormann, R. J. M. 2011. MDCK cell line with inducible allele B NS1 expression propagates delNS1 influenza virus to high titres. Vaccine 29(40): 6976- 6985.
91. Vodeiko, G. M., Mcinnis, J., Chizhikov, V., and Levandowski, R. A. 2003. Genetic and phenotypic analysis of reassortants of high growth and low growth strains of influenza B virus. Vaccine 21(25-26): 3867-3874.
92. Wacheck, V., Egorov, A., Groiss, F., Pfeiffer, A., Fuereder, T., Hoeflmayer, D., Kundi, M., et al. 2010. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. Journal of Infectious Diseases 201: 354-362.
93. Wang, Z. and Duke, G.M. 2007. Cloning of the canine RNA polymerase I promoter and establishment of reverse genetics for influenza A and B in MDCK cells. Virology Journal 4: 102.
94. Wang,W., Lu, B., Zhou, H., Suguitan, A.L.Jr., Cheng, X., Subbarao, K., Kemble, G. and Jin, H. 2010. Glycosylation at 158N of the hemagglutinin protein and receptor binding specificity synergistically affect the antigenicity and immunogenicity of a live attenuated H5N1 A/Vietnam/1203/2004 vaccine virus in ferrets. Journal of Virology 84(13): 6570-6577.
95. Watanabe, S., Watanabe, T. and Kawaoka, Y. 2009. Influenza A virus lacking M2 protein as a live attenuated vaccine. Journal of Virology 83: 5947-5950.
96. Watanabe, T.,Watanabe, S., Kida, H. and Kawaoka, Y. 2002. Influenza A virus with defective M2 ion channel activity as a live vaccine. Virology 299: 266-270.
97. Watanabe, T., Watanabe, S., Kim, J.H., Hatta, M. and Kawaoka, Y. 2008. Novel approach to the development of effective H5N1 influenza A virus vaccines: use of M2 cytoplasmic tail mutants. Journal of Virology 82(5): 2486-2492.
98. Whiteley, A., Major, D., Legastelois, I., Campitelli, L., Donatelli, I., Thompson, C., Zambon, M., et al. 2007. Generation of candidate human influenza vaccine strains in cell culture: rehearsing the European response to an H7N1 pandemic threat. Influenza and Other Respiratory Viruses 1: 157-166.
99. Wise, H. M., Foeglein, A., Sun, J., Dalton, R. M., Patel, S., Howard, W., Anderson, E. C., et al. 2009. A Complicated Message: Identification of a Novel PB1Related Protein Translated from Influenza A Virus Segment 2 mRNA. Journal of Virology 83: 8021-8031.
100. Xie, H., Liu, T. M., Lu, X., Wu, Z., Belser, J. A., Katz, J. M., Tumpey, T. M. and Ye, Z. 2009. A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice. Journal of Infectious Diseases 200: 1874-1883.
101. Yang, Z.Y., Wei, C. J., Kong, W. P., Wu, L., Xu, L., Smith, D. F., and Nabel, G. J. 2007. Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science 317(5839): 825-828.
102. Young, D. F., Carlos, T. S., Hagmaier, K., Fan, L., and Randall, R. E. 2007. AGS and other tissue culture cells can unknowingly be persistently infected with PIV5; a virus that blocks interferon signalling by degrading STAT1. Virology 365(1): 238-240.